- PR Newswire•yesterday
CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
This composition of matter patent provides additional coverage of the Company's base polymer system, and this and other U.S. and foreign patents in this family extend protection of CytoSorb and CytoSorbents' core technologies into 2026 in the U.S. and into 2031 in China, Japan, Russia, and Australia. Related patent applications are ongoing in other territories worldwide.
- PR Newswire•2 days ago
CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
MONMOUTH JUNCTION, N.J., March 27, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- PR Newswire•7 days ago
MONMOUTH JUNCTION, N.J., March 22, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CAR T-cell cancer immunotherapy pioneer, Dr. Carl H. June, M.D., will join its scientific advisory board to help guide applications of the company's technology in the treatment of cancer. Dr. Carl June, Director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine, stated, "Life-threatening inflammation caused by high grade cytokine release syndrome (CRS) has been observed in a wide range of cancer immunotherapies.
CTSO : Summary for CYTOSORBENTS COR - Yahoo Finance
Cytosorbents Corporation (CTSO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.55 x 400|
|Ask||5.70 x 1800|
|Day's Range||5.60 - 5.60|
|52 Week Range||3.87 - 6.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.94|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|